aspirin has been researched along with Cardiac Arrest, Sudden in 63 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance." | 9.14 | Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. ( Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S, 2009) |
| "To compare aspirin with anticoagulation with regard to risk of cardiac death and reinfarction in patients who received anistreplase thrombolysis for myocardial infarction." | 9.08 | A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. ( Chamberlain, DA; Julian, DG; Pocock, SJ, 1996) |
| "The Cardiac Arrhythmia Suppression Trial (CAST) was a multicenter double-blind, placebo-controlled study designed to determine whether suppression of ventricular ectopic activity by means of antiarrhythmic drugs (encainide, flecainide or moricizine) after acute myocardial infarction would reduce the incidence of arrhythmic death." | 9.07 | Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST). ( Barker, AH; Brooks, MM; Capone, R; Echt, DS; Greene, HL; Liebson, PR; Mitchell, LB; Peters, RW, 1994) |
| " Using a nested case-control design, we measured urinary 11-dehydro thromboxane B2 levels, a marker of in vivo thromboxane generation, in 488 cases treated with aspirin who had myocardial infarction, stroke, or cardiovascular death during 5 years of follow-up and in 488 sex- and age-matched control subjects also receiving aspirin who did not have an event." | 7.71 | Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. ( Eikelboom, JW; Hirsh, J; Johnston, M; Weitz, JI; Yi, Q; Yusuf, S, 2002) |
| "In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance." | 5.14 | Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. ( Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S, 2009) |
| "We extended the follow-up of 2473 patients from the Dutch TIA Trial (recruitment March 1986 to March 1989, all treated with aspirin; CIAO) and 186 Dutch participants of the European Atrial Fibrillation Trial (recruitment June 1988 to May 1992, 26% on anticoagulants during the trial; CIAF)." | 5.13 | Long-term occurrence of death and cardiovascular events in patients with transient ischaemic attack or minor ischaemic stroke: comparison between arterial and cardiac source of the index event. ( Algra, A; Gorter, JW; Kappelle, LJ; Koudstaal, PJ; van Gijn, J; van Wijk, I, 2008) |
| "Despite use of heparin and aspirin, 5-10% of patients with unstable angina develop myocardial infarction (MI) or refractory angina in the hospital." | 5.09 | Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial. ( Yusuf, S, 1999) |
| "To compare aspirin with anticoagulation with regard to risk of cardiac death and reinfarction in patients who received anistreplase thrombolysis for myocardial infarction." | 5.08 | A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. ( Chamberlain, DA; Julian, DG; Pocock, SJ, 1996) |
| "The Cardiac Arrhythmia Suppression Trial (CAST) was a multicenter double-blind, placebo-controlled study designed to determine whether suppression of ventricular ectopic activity by means of antiarrhythmic drugs (encainide, flecainide or moricizine) after acute myocardial infarction would reduce the incidence of arrhythmic death." | 5.07 | Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST). ( Barker, AH; Brooks, MM; Capone, R; Echt, DS; Greene, HL; Liebson, PR; Mitchell, LB; Peters, RW, 1994) |
| "The association between DAPT interruption and the rates of stent thrombosis (ST) and cardiac death/target-vessel myocardial infarction (CD/TVMI) in patients receiving a Resolute zotarolimus-eluting stent (R-ZES) was analysed in 4896 patients from the pooled RESOLUTE clinical programme." | 4.90 | Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. ( Belardi, JA; Brar, S; Kirtane, AJ; Liu, M; Rothman, M; Silber, S; Windecker, S, 2014) |
| "Platelet function analyses, which included measures of platelet aggregation and activation, were performed in 173 T2DM patients with coronary artery disease on chronic treatment with aspirin and clopidogrel." | 3.74 | Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. ( Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bass, TA; Bernardo, E; Costa, MA; Escaned, J; Fernandez-Ortiz, A; Guzman, LA; Hernández-Antolin, R; Jimenez-Quevedo, P; Macaya, C; Moreno, R; Palazuelos, J; Sabaté, M, 2007) |
| " Using a nested case-control design, we measured urinary 11-dehydro thromboxane B2 levels, a marker of in vivo thromboxane generation, in 488 cases treated with aspirin who had myocardial infarction, stroke, or cardiovascular death during 5 years of follow-up and in 488 sex- and age-matched control subjects also receiving aspirin who did not have an event." | 3.71 | Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. ( Eikelboom, JW; Hirsh, J; Johnston, M; Weitz, JI; Yi, Q; Yusuf, S, 2002) |
| " Targeted screening for subclinical coronary atherosclerosis with coronary artery calcium scores is prudent to guide appropriately dosed aspirin use to mitigate the increasing frequency of sports-related sudden cardiac death due to plaque rupture." | 2.61 | Aspirin to Prevent Sudden Cardiac Death in Athletes with High Coronary Artery Calcium Scores. ( Noakes, TD; Siegel, AJ, 2019) |
| "Untreated Kawasaki disease may lead to the formation of coronary artery aneurysms and sudden cardiac death in children." | 2.52 | Evidence-based management of Kawasaki disease in the emergency department. ( Kharbanda, A; Seaton, KK, 2015) |
| "Sudden cardiac death is a leading cause of death in Europe." | 2.46 | [Thrombolysis during cardio-pulmonary resuscitation]. ( Böttiger, BW; Padosch, SA; Spöhr, F; Teschendorf, P; Wetsch, WA, 2010) |
| "Aspirin resistance was assessed, using a variety of platelet function assays." | 2.44 | Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. ( Beattie, WS; Brister, SJ; Buchanan, MR; Krasopoulos, G, 2008) |
| " If the international normalized ratio (INR) was kept > 2 for a long period, by means of frequent check-ups and effective dosage adjustment, the chance of death, recurrent myocardial infarction or stroke was 30-50% lower than when acetylsalicylic acid only was used." | 2.43 | [Antithrombotic therapy after myocardial infarction: arguments for the use of acetylsalicylic acid and coumarin derivatives]. ( Brouwer, A; Verheugt, FW; Waskowsky, WM, 2005) |
| "Common aetiologies of sudden cardiac death in children include coronary anomalies, channelopathies, and cardiomyopathies." | 1.42 | Unusual cause of aborted sudden cardiac death in a teen athlete: homozygosity for the 4G allele of the plasminogen activase inhibitor type 1 gene. ( Batlivala, S; Knudson, JD; Phillips, SB, 2015) |
| "Aspirin use was associated with a lower risk of cardiovascular events (adjusted hazard ratio, 0." | 1.35 | Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease: the Women's Health Initiative Observational Study. ( Berger, JS; Brown, DL; Burke, GL; Kostis, JB; Langer, RD; Oberman, A; Wassertheil-Smoller, S; Wong, ND, 2009) |
| "The epidemiologic pattern of sudden cardiac death (SCD) may have changed in the modern treatment era of patients after an acute myocardial infarction (AMI)." | 1.33 | Frequency of sudden cardiac death among acute myocardial infarction survivors with optimized medical and revascularization therapy. ( Barthel, P; Bauer, A; Huikuri, HV; Mäkikallio, TH; Perkiömäki, JS; Schmidt, G; Schneider, R; Tapanainen, JM; Tulppo, MP, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 16 (25.40) | 18.2507 |
| 2000's | 30 (47.62) | 29.6817 |
| 2010's | 14 (22.22) | 24.3611 |
| 2020's | 3 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Siegel, AJ | 5 |
| Willemsen, LM | 1 |
| Janssen, PWA | 1 |
| Hackeng, CM | 1 |
| Kelder, JC | 1 |
| Tijssen, JGP | 1 |
| van Straten, AHM | 1 |
| Soliman-Hamad, MA | 1 |
| Deneer, VHM | 1 |
| Daeter, EJ | 1 |
| Sonker, U | 1 |
| Klein, P | 1 |
| Ten Berg, JM | 1 |
| Noakes, TD | 2 |
| Tofler, GH | 1 |
| Spinaze, M | 1 |
| Shaw, E | 1 |
| Buckley, T | 1 |
| Butterfield, JH | 1 |
| Weiler, CR | 1 |
| Silber, S | 1 |
| Kirtane, AJ | 1 |
| Belardi, JA | 1 |
| Liu, M | 1 |
| Brar, S | 1 |
| Rothman, M | 1 |
| Windecker, S | 1 |
| Phillips, SB | 1 |
| Batlivala, S | 1 |
| Knudson, JD | 1 |
| Seaton, KK | 1 |
| Kharbanda, A | 1 |
| Lee, SY | 1 |
| Hong, MK | 3 |
| Shin, DH | 1 |
| Kim, JS | 1 |
| Kim, BK | 2 |
| Ko, YG | 1 |
| Choi, D | 1 |
| Jang, Y | 2 |
| Kim, HS | 2 |
| Valgimigli, M | 2 |
| Palmerini, T | 2 |
| Stone, GW | 2 |
| Della Riva, D | 1 |
| Benedetto, U | 1 |
| Bacchi Reggiani, L | 1 |
| Feres, F | 1 |
| Abizaid, A | 1 |
| Gilard, M | 1 |
| Morice, MC | 1 |
| Park, KW | 1 |
| Colombo, A | 1 |
| Chieffo, A | 1 |
| Sangiorgi, D | 1 |
| Biondi-Zoccai, G | 1 |
| Généreux, P | 1 |
| Angelini, GD | 1 |
| Pufulete, M | 1 |
| White, J | 1 |
| Bhatt, DL | 1 |
| Fimbres, AM | 1 |
| Shulman, ST | 1 |
| Jolly, SS | 1 |
| Pogue, J | 1 |
| Haladyn, K | 1 |
| Peters, RJ | 1 |
| Fox, KA | 1 |
| Avezum, A | 1 |
| Gersh, BJ | 1 |
| Rupprecht, HJ | 1 |
| Yusuf, S | 3 |
| Mehta, SR | 1 |
| Wang, ZJ | 1 |
| Zhou, YJ | 1 |
| Liu, YY | 1 |
| Yu, M | 1 |
| Shi, DM | 1 |
| Zhao, YX | 1 |
| Guo, YH | 1 |
| Cheng, WJ | 1 |
| Nie, B | 1 |
| Ge, HL | 1 |
| Jia, DA | 1 |
| Yang, SW | 1 |
| Yan, ZX | 1 |
| Berger, JS | 1 |
| Brown, DL | 1 |
| Burke, GL | 1 |
| Oberman, A | 1 |
| Kostis, JB | 1 |
| Langer, RD | 1 |
| Wong, ND | 1 |
| Wassertheil-Smoller, S | 1 |
| Moerenhout, CM | 1 |
| Claeys, MJ | 1 |
| Haine, S | 1 |
| Miljoen, H | 1 |
| Bosmans, JM | 1 |
| Vertessen, F | 1 |
| Kluppels, K | 1 |
| Van der Planken, M | 1 |
| Vrints, CJ | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Sidorenko, BA | 1 |
| Fettser, DV | 1 |
| Batyraliev, TA | 2 |
| Niiazova-Karben, ZA | 1 |
| Besnili, F | 1 |
| Wetsch, WA | 1 |
| Spöhr, F | 1 |
| Teschendorf, P | 1 |
| Böttiger, BW | 1 |
| Padosch, SA | 1 |
| Aydinalp, A | 1 |
| Atar, I | 1 |
| Altin, C | 1 |
| Gülmez, O | 1 |
| Atar, A | 1 |
| Açikel, S | 1 |
| Bozbaş, H | 1 |
| Yildirir, A | 1 |
| Müderrisoğlu, H | 1 |
| Hayek, E | 1 |
| Griffin, B | 1 |
| Czuriga, I | 1 |
| Jönsson, B | 1 |
| Hansson, L | 1 |
| Stålhammar, NO | 1 |
| Ishikawa, K | 1 |
| Shalaev, SV | 1 |
| Mintz, GS | 1 |
| Lee, CW | 1 |
| Kim, YH | 1 |
| Lee, SW | 1 |
| Song, JM | 1 |
| Han, KH | 1 |
| Kang, DH | 1 |
| Song, JK | 1 |
| Kim, JJ | 1 |
| Park, SW | 1 |
| Park, SJ | 1 |
| Waskowsky, WM | 1 |
| Brouwer, A | 1 |
| Verheugt, FW | 1 |
| Arellano, FM | 1 |
| Rzeczuch, K | 1 |
| Szajn, G | 1 |
| Jankowska, E | 1 |
| Kaczmarek, A | 1 |
| Derkacz, A | 1 |
| Porada, A | 1 |
| Telichowski, A | 1 |
| Banasiak, W | 1 |
| Ponikowski, P | 1 |
| Mäkikallio, TH | 1 |
| Barthel, P | 1 |
| Schneider, R | 1 |
| Bauer, A | 1 |
| Tapanainen, JM | 1 |
| Tulppo, MP | 1 |
| Perkiömäki, JS | 1 |
| Schmidt, G | 1 |
| Huikuri, HV | 1 |
| Finn, AV | 1 |
| Joner, M | 1 |
| Nakazawa, G | 1 |
| Kolodgie, F | 1 |
| Newell, J | 1 |
| John, MC | 1 |
| Gold, HK | 1 |
| Virmani, R | 1 |
| Jiménez-Quevedo, P | 2 |
| Sabaté, M | 2 |
| Angiolillo, DJ | 2 |
| Alfonso, F | 2 |
| Hernández-Antolín, R | 2 |
| SanMartín, M | 1 |
| Gómez-Hospital, JA | 1 |
| Bañuelos, C | 2 |
| Escaned, J | 2 |
| Moreno, R | 2 |
| Fernández, C | 1 |
| Fernández-Avilés, F | 1 |
| Macaya, C | 2 |
| Bernardo, E | 1 |
| Costa, MA | 1 |
| Palazuelos, J | 1 |
| Guzman, LA | 1 |
| Bass, TA | 1 |
| Fernandez-Ortiz, A | 1 |
| Simon, DI | 1 |
| Schmaier, AH | 1 |
| van Wijk, I | 1 |
| Koudstaal, PJ | 2 |
| Kappelle, LJ | 2 |
| van Gijn, J | 2 |
| Gorter, JW | 1 |
| Algra, A | 2 |
| Krasopoulos, G | 1 |
| Brister, SJ | 1 |
| Beattie, WS | 1 |
| Buchanan, MR | 1 |
| Pershukov, IV | 1 |
| Britton, M | 1 |
| Peters, RW | 1 |
| Mitchell, LB | 1 |
| Brooks, MM | 1 |
| Echt, DS | 1 |
| Barker, AH | 1 |
| Capone, R | 1 |
| Liebson, PR | 1 |
| Greene, HL | 1 |
| Szczeklik, A | 1 |
| Cambou, JP | 1 |
| Ferrières, J | 1 |
| Ruidavets, JB | 1 |
| Ducimetière, P | 2 |
| Julian, DG | 1 |
| Chamberlain, DA | 1 |
| Pocock, SJ | 1 |
| Schühlen, H | 1 |
| Hadamitzky, M | 1 |
| Walter, H | 1 |
| Ulm, K | 1 |
| Schömig, A | 1 |
| Weber, AA | 1 |
| Schrör, K | 1 |
| Ohsuzu, F | 1 |
| Katsushika, S | 1 |
| Akanuma, M | 1 |
| Nakamura, H | 1 |
| Harada, H | 1 |
| Satoh, M | 1 |
| Hiroi, S | 1 |
| Kimura, A | 1 |
| Saniabadi, AR | 1 |
| Takeich, S | 1 |
| Yukawa, N | 1 |
| Nakajima, Y | 1 |
| Umemura, K | 1 |
| Nakashima, M | 1 |
| Klootwijk, P | 1 |
| Meij, S | 1 |
| Melkert, R | 1 |
| Lenderink, T | 1 |
| Simoons, ML | 1 |
| Kausar, SA | 1 |
| Anand, SS | 1 |
| Holm, J | 1 |
| Hillarp, A | 1 |
| Erhardt, L | 1 |
| Berntorp, E | 1 |
| Heeschen, C | 1 |
| Hamm, CW | 1 |
| Meade, TW | 1 |
| Brennan, PJ | 1 |
| Cleland, JG | 1 |
| Massie, BM | 1 |
| Packer, M | 1 |
| Guize, L | 1 |
| Consoli, SM | 1 |
| Kolsky, H | 1 |
| Raynaud, P | 1 |
| Walch, JM | 1 |
| Paul-Dauphin, A | 1 |
| Duprat-Lomon, I | 1 |
| Peterson, JG | 1 |
| Topol, EJ | 1 |
| Sapp, SK | 1 |
| Young, JB | 1 |
| Lincoff, AM | 1 |
| Lauer, MS | 1 |
| Fihn, SD | 1 |
| Williams, SV | 1 |
| Daley, J | 1 |
| Gibbons, RJ | 1 |
| Baron, BW | 1 |
| Martin, MS | 1 |
| Sucharetza, BS | 1 |
| Jeon, H | 1 |
| Baron, JM | 1 |
| Eikelboom, JW | 1 |
| Hirsh, J | 1 |
| Weitz, JI | 1 |
| Johnston, M | 1 |
| Yi, Q | 1 |
| Newby, LK | 1 |
| Califf, RM | 1 |
| White, HD | 1 |
| Harrington, RA | 1 |
| Van de Werf, F | 1 |
| Granger, CB | 1 |
| Simes, RJ | 1 |
| Hasselblad, V | 1 |
| Armstrong, PW | 1 |
| Albert, CM | 1 |
| Ma, J | 1 |
| Rifai, N | 1 |
| Stampfer, MJ | 1 |
| Ridker, PM | 1 |
| Pop, GA | 1 |
| van Latum, JC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Trial Investigating The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery (The POPular CABG Study)[NCT02352402] | Phase 3 | 487 participants (Anticipated) | Interventional | 2015-03-31 | Active, not recruiting | ||
| RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population[NCT00752128] | 2,349 participants (Actual) | Observational | 2008-08-31 | Completed | |||
| Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835] | 1,492 participants (Anticipated) | Observational [Patient Registry] | 2019-08-01 | Recruiting | |||
| A Clinical Evaluation of the Medtronic Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2mm[NCT00726453] | 1,516 participants (Actual) | Interventional | 2008-07-31 | Completed | |||
| The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries[NCT00927940] | 100 participants (Actual) | Interventional | 2009-03-31 | Completed | |||
| RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention[NCT00617084] | Phase 4 | 2,292 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Revascularization With Paclitaxel-coated Balloon Angioplasty Versus Drug-eluting Stenting in Acute Myocardial Infarction - a Randomized Controlled Trial.[NCT02219802] | 120 participants (Anticipated) | Interventional | 2014-08-31 | Not yet recruiting | |||
| Finnish-German Prospective, Observational Follow-up Study on Risk Assessment of Mortality After Myocardial Infarction[NCT00828698] | 0 participants | Observational | 1996-01-31 | Completed | |||
| A Prospective Optical Coherence Tomography Study on Completeness of Strut Coverage and Vessel Wall Response at 3-6 and 9 Months Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease[NCT00704145] | Phase 4 | 30 participants (Anticipated) | Interventional | 2007-11-30 | Completed | ||
| Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265] | 31 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Vessel Injury in Relation With Strut Thickness Assessed by OCT (VISTA): A Comparison of Vascular Injury Induced by a Polymer Free Sirolimus and Probucol Eluting Stent and a Biodegradable-polymer Biolimus-eluting Stent[NCT03026465] | Phase 4 | 50 participants (Actual) | Interventional | 2017-02-16 | Completed | ||
| In-Vivo Vascular Response of Sirolimus-,Paclitaxel- and Zotarolimus-Eluting Stents in Long Lesions Requiring Overlapping. A Prospective, Randomized, Controlled Study Using Optical Coherence Tomography[NCT00693030] | Phase 4 | 77 participants (Anticipated) | Interventional | 2006-08-31 | Recruiting | ||
| The Optical Coherence Tomography Drug Eluting Stent Investigation(OCTDESI)[NCT00776204] | 60 participants (Actual) | Interventional | 2008-05-31 | Completed | |||
| Frequency Domain Imaging to Determine Stent Strut Coverage and Duration of Anti-Platelet Treatment After Endeavor Stent Placement[NCT01219894] | 0 participants (Actual) | Observational | 2010-11-30 | Withdrawn (stopped due to Number of patients to meet individual IDE requirements was not obtained.) | |||
| Effect of TCFA on Neointimal Coverage After EXCEL Biodegradable Polymer-coated Sirolimus-eluting Stents Implantation at 9 Months Follow-up: Evaluated by Optical Coherence Tomography and Fractional Flow Reserve[NCT02384837] | 33 participants (Actual) | Observational | 2014-12-31 | Completed | |||
| Optical Frequency Domain Imaging (OFDI) Determined Stent Strut Coverage and Plaque Morphology After RESOLUTE Stent Placement in Non-Insulin Dependent Diabetics Presenting With Acute Coronary Syndrome (ACS)[NCT01794949] | 8 participants (Actual) | Interventional | 2013-09-30 | Completed | |||
| The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events[NCT02616497] | Phase 4 | 1,220 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Aspirin Resistance in Obstructive Sleep Apnea Patients (ARISA Trial)[NCT03930875] | 63 participants (Actual) | Observational | 2017-12-12 | Completed | |||
| [NCT00000526] | Phase 3 | 0 participants | Interventional | 1986-08-31 | Completed | ||
| Heart Rate Lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease[NCT01365286] | Phase 4 | 40 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00752128)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Cardiac Death or Target Vessel MI | 4.2 |
(NCT00752128)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Overall Stent Thrombosis (Definite and Probable-ARC) | 0.9 |
(NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 1.3 |
Major Adverse Cardiac Event (MACE) composite endpoint and each individual component (death, Target Vessel MI (Q wave and non-Q wave), emergent coronary bypass surgery (CABG), or clinically-driven repeat Target Lesion Revascularization (TLR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 5.5 |
Stent Thrombosis (ST) (as determined by historic and ARC definitions). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 0.1 |
Target Lesion Failure (TLF) at 12 months post-procedure, defined as Cardiac Death, Target Vessel Myocardial Infarction (TVMI) (Q wave and non-Q wave) or clinically-driven Target Lesion Revascularization (TLR) by percutaneous or surgical methods. (NCT00726453)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 4.7 |
Target Vessel Failure (TVF) composite endpoint and each individual component (Cardiac Death, Target Vessel MI, or clinically-driven Target Vessel Revascularization (TVR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 6.3 |
Target Vessel MI (as determined by extended historical and ARC definitions). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of eligible participants (Number) |
|---|---|
| Primary Enrollment Group | 1.4 |
The difference between the post-procedure immediate minimal lumen diameter (MLD) and follow up angigraphy MLD (NCT00927940)
Timeframe: Post procedure, 8 Months
| Intervention | mm (Mean) |
|---|---|
| Zotarolimus Eluting Stent | 0.13 |
Major Secondary Endpoint Target lesion fature (TLF) is defined as cardiac death, target vessel myocardial infarction(Q wave and non-Q wave), or clinically-driven target lesion revascularization (TLR) by percutaneous or surgical methods. (NCT00927940)
Timeframe: 12 months
| Intervention | percentage of participants with TLF (Number) |
|---|---|
| Zotarolims Eluting Stent | 4.0 |
In Stent Percent Diameter Stenosis at thirteen months. In Stent Percent Diameter Stenosis: measured percent of diameter stenosis at the region of the stent (calculated as 100x(RVD-MLD)/RVD using the mean values from 2 orthogonal views by QCA. RVD (Reference Vessel Diameter): average of normal segments within 10mm proximal and distal to target lesion from 2 orthogonal views using QCA. MLD (Minimal Lumen Diameter): average of 2 orthogonal views of the narrowest point wihtin the area of assessment. MLD measured during QCA by the angiographic core laboratory. (NCT00617084)
Timeframe: 13 Months
| Intervention | Percentage diameter stenosis (Mean) |
|---|---|
| 1. Resolute - 12-13 Months | 21.65 |
| 2. XIENCE V - 12-13 Months | 19.76 |
Percentage of participants that had either Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel)or Target Lesion Revascularization (TLR, clinically indicated) after one year. MI: Q MI if new pathological Q waves and chest pain, non Q MI if CK elevated more than two times normal, troponin elevated more than normal, according to ARC definitions. TLR, clinically indicated if associated with ischemic symptoms and angiographic min lumen diameter bigger than fifty percent by QCA or without symptoms and min lumen diameter bigger than seventy percent. Measure average. (NCT00617084)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| 1. Resolute - 12-13 Months | 8.2 |
| 2. XIENCE V - 12-13 Months | 8.3 |
Assessment of vascular healing 6 months after Resolute Integrity placement in non-diabetic patients and patients with non-insulin dependent diabetes presenting with acute coronary syndrome (ACS) using optical frequency domain imaging (OFDI). Vascular healing will be measured by percent covered stents as determined by OFDI. A higher percentage of stent coverage indicates increased endothelial regrowth, which is an essential component for the maintenance of long-term luminal patency. (NCT01794949)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| 85% up to 90% stent coverage | 90% up to 95% stent coverage | 95% or greater percent stent coverage | |
| NIDDM Patients Receiving the Resolute Stent | 0 | 1 | 0 |
| Non-diabetic Patients Receiving the Resolute Stent | 1 | 3 | 1 |
17 reviews available for aspirin and Cardiac Arrest, Sudden
| Article | Year |
|---|---|
Aspirin to Prevent Sudden Cardiac Death in Athletes with High Coronary Artery Calcium Scores.
Topics: Aspirin; Athletes; Coronary Artery Disease; Death, Sudden, Cardiac; Humans | 2019 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Evidence-based management of Kawasaki disease in the emergency department.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal; Aspirin; Child, Preschool | 2015 |
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
Topics: Acute Coronary Syndrome; Analysis of Variance; Aspirin; Blood Vessel Prosthesis Implantation; Clopid | 2017 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular D | 2010 |
[Thrombolysis during cardio-pulmonary resuscitation].
Topics: Aspirin; Cardiopulmonary Resuscitation; Contraindications; Death, Sudden, Cardiac; Fibrinolytic Agen | 2010 |
Pheidippides redux: reducing risk for acute cardiac events during marathon running.
Topics: Aspirin; Death, Sudden, Cardiac; Humans; Platelet Aggregation Inhibitors; Risk Factors; Running | 2012 |
[Secondary prevention after myocardial infarction].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 2002 |
[Anticoagulant, antiplatelet agents].
Topics: Anticoagulants; Aspirin; Death, Sudden, Cardiac; Dipyridamole; Drug Therapy, Combination; Heparin; H | 2003 |
[Antiplatelet drugs in prevention of complications of arteriosclerotic diseases: it is necessary to move beyond aspirin].
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Drug Therapy, Combination; Hu | 2003 |
[Antithrombotic therapy after myocardial infarction: arguments for the use of acetylsalicylic acid and coumarin derivatives].
Topics: Anticoagulants; Aspirin; Clopidogrel; Coumarins; Death, Sudden, Cardiac; Fibrinolytic Agents; Humans | 2005 |
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Death, Sudden, Cardiac; Drug Resistance; | 2008 |
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Death, Sudden, Cardiac; Drug Resistance; | 2008 |
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Death, Sudden, Cardiac; Drug Resistance; | 2008 |
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Death, Sudden, Cardiac; Drug Resistance; | 2008 |
[Drug-eluting stent thrombosis and its pharmacological prevention].
Topics: Aspirin; Clopidogrel; Death, Sudden, Cardiac; Drug-Eluting Stents; Fibrinolytic Agents; Humans; Inci | 2007 |
Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin.
Topics: Aspirin; Death, Sudden, Cardiac; Depression, Chemical; Female; Fibrinolysis; Fibrinolytic Agents; Hu | 1995 |
[Pharmacology of ticlopidine and clopidogrel in comparison with acetylsalicylic acid].
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Coronary Thrombosis; Death, Sudden, Cardiac; Humans | 1997 |
Four patients with both thrombotic thrombocytopenic purpura and autoimmune thrombocytopenic purpura: the concept of a mixed immune thrombocytopenia syndrome and indications for plasma exchange.
Topics: Adult; Arthritis, Rheumatoid; Aspirin; Autoimmune Diseases; Blood Platelets; Combined Modality Thera | 2001 |
The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events.
Topics: Administration, Oral; Aspirin; Coronary Disease; Death, Sudden, Cardiac; Humans; Myocardial Infarcti | 2002 |
17 trials available for aspirin and Cardiac Arrest, Sudden
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled trial investigating the effect of ticagrelor on saphenous vein graft patency in patients undergoing coronary artery bypass grafting surgery-Rationale and design of the POPular CABG trial.
Topics: Aged; Aspirin; Computed Tomography Angiography; Coronary Angiography; Coronary Artery Bypass; Death, | 2020 |
Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Dose-Response Relations | 2017 |
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Death, Sudden, Cardiac; Double-Blind Method; F | 2009 |
Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension.
Topics: Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Calcium Channel Blockers; Cost-Benefit Analy | 2003 |
Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
Topics: Aged; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Death, | 2007 |
Long-term occurrence of death and cardiovascular events in patients with transient ischaemic attack or minor ischaemic stroke: comparison between arterial and cardiac source of the index event.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cause of Death; Cerebral Hemorrhage; Cerebral In | 2008 |
The role of autopsy findings in multicenter treatment evaluations as exemplified by two aspirin trials.
Topics: Aspirin; Autopsy; Cause of Death; Cerebral Infarction; Death, Sudden, Cardiac; Diagnostic Errors; Do | 1993 |
Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST).
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aspirin; Circadian Rhythm; Death, Sudden, Cardia | 1994 |
A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial.
Topics: Anistreplase; Anticoagulants; Aspirin; Death, Sudden, Cardiac; Female; Heparin; Humans; Male; Myocar | 1996 |
Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISA
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Combined Modality | 1997 |
Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE).
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 1998 |
Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial.
Topics: Adult; Angina, Unstable; Anticoagulants; Aspirin; Death, Sudden, Cardiac; Double-Blind Method; Drug | 1999 |
The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Pilot Study: evaluation of acute and long-term therapies for patients with acute coronary syndromes without ST elevation.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Aspirin; Canada; Death, Sudden, Cardiac; Dose | 1999 |
Changes in levels of factor VII and protein S after acute myocardial infarction: effects of low-dose warfarin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antigens; Aspirin; Brain Ischemia; Death, Sudden, Ca | 1999 |
Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial.
Topics: Aged; Aspirin; Blood Pressure; Death, Sudden, Cardiac; Humans; Male; Middle Aged; Myocardial Infarct | 2000 |
Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; beta | 2002 |
Risk of cardiac events in atypical transient ischaemic attack or minor stroke. The Dutch TIA Study Group.
Topics: Aged; Aspirin; Atenolol; Cerebrovascular Disorders; Death, Sudden, Cardiac; Diagnosis, Differential; | 1992 |
29 other studies available for aspirin and Cardiac Arrest, Sudden
| Article | Year |
|---|---|
Pre-Race Aspirin to Enhance Primary Prevention of Marathon-Related Cardiac Arrest: Confronting Pheidippides' Legacy.
Topics: Aspirin; Death, Sudden, Cardiac; Heart Arrest; Humans; Marathon Running; Primary Prevention | 2023 |
Aspirin to Reduce Risk for Sudden Cardiac Death in Athletes With Elevated C-Reactive Protein Levels.
Topics: Aspirin; Athletes; C-Reactive Protein; Coronary Thrombosis; Death, Sudden, Cardiac; Fibrinolytic Age | 2020 |
Can pre-race aspirin prevent sudden cardiac death during marathons?
Topics: Aspirin; Death, Sudden, Cardiac; Humans; Male; Middle Aged; Running | 2017 |
Therapy for triggered acute risk prevention in subjects at increased cardiovascular risk.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Death, Sudden, Cardiac; Drug Therapy, | 2013 |
Presentation of untreated systemic mastocytosis as recurrent, pulseless-electrical-activity cardiac arrests resistant to cardiac pacemaker.
Topics: Acetates; Aged, 80 and over; Aspirin; Cromolyn Sodium; Cyclopropanes; Death, Sudden, Cardiac; Drug T | 2014 |
Unusual cause of aborted sudden cardiac death in a teen athlete: homozygosity for the 4G allele of the plasminogen activase inhibitor type 1 gene.
Topics: Adolescent; Alleles; Aspirin; Athletes; Cardiac Catheterization; Clopidogrel; Death, Sudden, Cardiac | 2015 |
Kawasaki disease.
Topics: Algorithms; Aspirin; Child, Preschool; Cross-Sectional Studies; Death, Sudden, Cardiac; Diagnosis, D | 2008 |
Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis; Body Mass Index; Clopidogrel; Coro | 2009 |
Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease: the Women's Health Initiative Observational Study.
Topics: Aged; Angina Pectoris; Aspirin; Cardiovascular Diseases; Death, Sudden, Cardiac; Dose-Response Relat | 2009 |
Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Vessels; | 2010 |
Platelet function analysis with two different doses of aspirin.
Topics: Analysis of Variance; Aspirin; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Female; Hea | 2010 |
Mitral valve prolapse: old beliefs yield to new knowledge.
Topics: Adrenergic beta-Antagonists; Antibiotic Prophylaxis; Anticoagulants; Arrhythmias, Cardiac; Aspirin; | 2002 |
Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation.
Topics: Aged; Aspirin; Atherectomy, Coronary; Catheterization; Cilostazol; Combined Modality Therapy; Corona | 2004 |
The withdrawal of rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; | 2005 |
Borderline coronary lesions may lead to serious coronary events--long-term outcome in 65 conservatively treated patients.
Topics: Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Coronary | 2005 |
Frequency of sudden cardiac death among acute myocardial infarction survivors with optimized medical and revascularization therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Death, Sudden, Cardi | 2006 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk.
Topics: Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudden, Car | 2007 |
[Epidemiology according to the European and French scales of myocardial infarction. Data of the MONICA project].
Topics: Adrenergic beta-Antagonists; Adult; Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Aspir | 1996 |
Hypertrophic obstructive cardiomyopathy due to a novel T-to-A transition at codon 624 in the beta-myosin heavy chain (beta-MHC) gene possibly related to the sudden death.
Topics: Amyl Nitrite; Asparagine; Aspirin; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Codon; Death, | 1997 |
Apo E4/3-rich remnant lipoproteins and platelet aggregation: a case report.
Topics: 2-Chloroadenosine; Adenosine Diphosphate; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; A | 1998 |
Heart failure: a diagnostic and therapeutic dilemma in elderly patients.
Topics: Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trials as Topic; Death | 1999 |
Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists.
Topics: Administration, Oral; Aspirin; Death, Sudden, Cardiac; Humans; Myocardial Infarction; Oximes; Piperi | 2000 |
Sudden death in heart failure: vascular or electrical?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Death, Sudden, Cardi | 1999 |
[One-year follow-up of a population of patients with angina. Factors influencing mortality and occurrence of cardiovascular events. Results of the ELAN study].
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Angina Pectoris; Anti-Infl | 2000 |
Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Disease; Cyclooxygenase Inhibitors | 2000 |
Guidelines for the management of patients with chronic stable angina: treatment.
Topics: Adrenergic beta-Antagonists; Adult; Algorithms; Angina Pectoris; Aspirin; Calcium Channel Blockers; | 2001 |
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Canada; Cardiovascular Diseases; Case-Contr | 2002 |